Search

Skin disorders among individuals receiving palliative care may be associated with the primary condition or underlying comorbidities and patients may experience pruritus, discomfort or pain. Common conditions include xerosis, pressure ulcers, intertrigo, superficial fungal infections, telogen effluvium, pruritus, herpes zoster, eczematous disorders and edema. During end-of-life care, there is reduced skin perfusion and metabolism hence leading to susceptibility to infection, pressure and injury. Other factors affecting the skin include limited mobility, nutritional deficits and immunosuppression. Although treatment strategies for each skin condition are usually aligned with standard protocols, considerations among these patients include limited life-expectancies, potential treatment burden, drug-drug interactions as well as comfort-directed rather than cure-directed therapy. For patients with xerosis cutis, the regular use of moisturisers is recommended. The management and prevention of pressure ulcers include the strategies of skin assessment and care, pressure redistribution, nutrition and hydration and ulcer care. Superficial fungal infections require treatment with appropriate topical and/or systemic antifungals while antivirals and adjunctive treatment can be prescribed for herpes zoster. Treatment and symptom control of skin disorders in this population can improve quality of life and patients' comfort level. [ABSTRACT FROM AUTHOR]

Naevus sebaceus is a cutaneous hamartoma with the potential of developing into benign or malignant neoplasms. Syringocystadenoma papilliferum (SCAP) have been reported to originate from naevus sebaceus. SCAP is a rare, benign adnexal skin tumour of apocrine or eccrine type of differentiation which typically presents as a nodule or a plaque on the scalp or face. We report a case of syringocystadenoma papilliferum arising in an undiagnosed pre-existing naevus sebaceus in a 56-year-old female. [ABSTRACT FROM AUTHOR]

Inflammatory markers such as neutrophil-lymphocyte ratio (NLR) and eosinophil count are known prognostic indicators for the severity of Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). This study explores the correlation of systemic immune-inflammation index (SII), platelet-lymphocyte ratio (PLR) and NLR with Severity-of-Illness Score for Toxic Epidermal Necrolysis (SCORTEN) and patient outcomes. A retrospective audit of 34 patients with SJS/TEN (25 SJS, 3 SJS/TEN overlap, 6 TEN) was conducted from 2018 to 2022. Mean admission values were SII 1597 (SD 1904), NLR 6.52 (SD 5.99) and PLR 202 (SD 135). Cut-off values for predicting mortality were SII 1238 [area under receiver operating characteristic curve (AUROC) 0.82], NLR 8.32 (AUROC 0.80) and PLR 285 (AUROC 0.78). Multiple logistic regression using a backward stepwise method identified SCORTEN as a significant factor associated with mortality (P = 0.03) after adjusting for SII, NLR and PLR. None of the inflammatory markers significantly predicted mortality, although PLR at admission may be a potential risk factor (P = 0.05)., Competing Interests: Conflicts of interest The authors declare no conflicts of interest., (© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)